[go: up one dir, main page]

CA2400215A1 - Peptides de liaison hla et utilisations de ces derniers - Google Patents

Peptides de liaison hla et utilisations de ces derniers Download PDF

Info

Publication number
CA2400215A1
CA2400215A1 CA002400215A CA2400215A CA2400215A1 CA 2400215 A1 CA2400215 A1 CA 2400215A1 CA 002400215 A CA002400215 A CA 002400215A CA 2400215 A CA2400215 A CA 2400215A CA 2400215 A1 CA2400215 A1 CA 2400215A1
Authority
CA
Canada
Prior art keywords
peptides
peptide
cells
ctl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400215A
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
W. Martin Kast
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400215A1 publication Critical patent/CA2400215A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne les moyens et les procédés qui permettent de sélectionner des peptides immunogènes et des compositions de peptides immunogènes qui sont capables de lier spécifiquement des glycoprotéines codées par des allèles HLA et d'induire une activation des cellules T dans des cellules T restreintes par l'allèle. Ces peptides sont utiles pour solliciter une réponse immunitaire contre un antigène désiré.
CA002400215A 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers Abandoned CA2400215A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/004655 WO2001062776A1 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Publications (1)

Publication Number Publication Date
CA2400215A1 true CA2400215A1 (fr) 2001-08-30

Family

ID=21741082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400215A Abandoned CA2400215A1 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Country Status (8)

Country Link
EP (1) EP1263775A4 (fr)
JP (1) JP2003524016A (fr)
CN (1) CN1452634A (fr)
AU (1) AU2000232427A1 (fr)
BR (1) BR0017136A (fr)
CA (1) CA2400215A1 (fr)
MX (1) MXPA02008219A (fr)
WO (1) WO2001062776A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5898400A (en) * 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
AU2001242190A1 (en) * 2000-03-31 2001-10-15 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2006009920A2 (fr) 2004-06-17 2006-01-26 Mannkind Corporation Analogues d'epitopes
EP2333060B1 (fr) * 2005-01-25 2016-05-25 NEC Corporation Peptides se liant au HLA, fragments d'ADN codant pour lesdits peptides et vecteurs recombinants
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
JP5416968B2 (ja) * 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
CN1948333B (zh) * 2005-10-14 2010-12-08 中国人民解放军第二军医大学 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
EP2066689A4 (fr) * 2006-09-07 2010-04-28 Univ South Florida Peptides hyd1 en tant qu'agents anticancereux
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
CA2793838C (fr) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Inhibiteurs des interactions de l'integrine pour traiter le cancer
JP5930967B2 (ja) * 2010-09-08 2016-06-08 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
WO2018065628A2 (fr) 2016-10-07 2018-04-12 Enterome Variants de séquence de microbiote d'épitopes antigéniques associés à une tumeur
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
CN117801066A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
US11897927B2 (en) 2016-11-30 2024-02-13 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CA3081710A1 (fr) * 2017-11-08 2019-05-16 Advaxis, Inc. Peptides heteroclitiques immunogenes issus de proteines associees au cancer et procedes d'utilisation de ces peptides
FI3773689T3 (fi) 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157510A1 (fr) * 1993-03-05 1994-09-15 Howard M. Grey Peptides liants hla-a2.1 et leurs utilisations
AU2658897A (en) * 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
AU3672597A (en) * 1996-07-25 1998-02-20 Johns Hopkins University, The Novel genes of kaposi's sarcoma associated herpesvirus
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Also Published As

Publication number Publication date
EP1263775A1 (fr) 2002-12-11
BR0017136A (pt) 2003-02-25
EP1263775A4 (fr) 2004-10-06
MXPA02008219A (es) 2005-06-30
WO2001062776A1 (fr) 2001-08-30
CN1452634A (zh) 2003-10-29
JP2003524016A (ja) 2003-08-12
AU2000232427A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
US7252829B1 (en) HLA binding peptides and their uses
EP1917970B1 (fr) Peptides se fixant au Hla et leurs utilisations
AU725550B2 (en) HLA binding peptides and their uses
CA2248667C (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
EP1911461A2 (fr) Peptides de liaisons HLA de classe I et II et leurs utilisations
CA2400215A1 (fr) Peptides de liaison hla et utilisations de ces derniers
JP2010090167A (ja) Ｈｌａ結合ペプチドおよびそれらの用途
US20020177694A1 (en) Hla binding peptides and their uses
CA2420225A1 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
EP1320377B1 (fr) Peptides de liaison aux hla et leurs utilisations
CA2421448A1 (fr) Peptides de fixation de hla et leurs utilisations
EP1767542B1 (fr) Peptides de fixation de HLA-A2.1 et leurs utilisation
KR20030036139A (ko) Ｈｌａ 결합 펩티드 및 이의 용도
JP2010001303A (ja) Ｈｌａ結合ペプチド及びその使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130802